Physiologically based pharmacokinetic modeling of fluorescently labeled block copolymer nanoparticles for controlled drug delivery in leukemia therapy

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 3, 2015, Pages 167-174

  Gilkey, M J ^a   Krishnan, V ^a,b   Scheetz, L ^a   Jia, X ^a   Rajasekaran, A K ^a,c   Dhurjati, P S ^a  

^a UNIVERSITY OF DELAWARE   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPOLYMER; DEXAMETHASONE; FLUORESCENT DYE; NANOPARTICLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG LIVER LEVEL; FEMALE; FLUORESCENCE; KIDNEY; LIVER; MAXIMUM PLASMA CONCENTRATION; MOUSE; NANOENCAPSULATION; NONHUMAN; PHARMACOKINETICS; PLASMA; PRIORITY JOURNAL; SIMULATION; SPLEEN; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION;

EID: 84936770110     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.13     Document Type: Article

References (23)

1. Bischoff, K.B., Dedrick, R.L., Zaharko, D.S., &, Longstreth, J.A., Methotrexate pharmacokinetics. J Pharm. Sci. 60, 1128-1133 (1971).
2. Jones, H., &, Rowland-Yeo, K., Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol. 2, e63 (2013).
3. Rowland, M., Balant, L., &, Peck, C., Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, 29-30 May 2002). AAPS J. 6, 56-67 (2004).
4. Bischoff, K.B., Physiological pharmacokinetics. Bull. Math. Biol. 48, 309-322 (1986).
5. Li, M., Al-Jamal, K.T., Kostarelos, K., &, Reineke, J., Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano. 4, 6303-6317 (2010).
6. Birnbaum, L., et al,. Physiological parameter values for PBPK models. A report prepared by the International Life Sciences Institute Risk Science Institute. U.S. Environmental Protection Agency Office of Health and Environmental Assessment (1994).
7. Davies, B., &, Morris, T., Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093-1095 (1993).
8. Hu, Z.Y., Lu, J., &, Zhao, Y., A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans. Br. J. Pharmacol. 171, 2778-2789 (2014).
9. Shah, D.K., &, Betts A.M., Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J. Pharmacokinet. Pharmacodyn. 39, 67-86 (2012).
10. Horton, S., Tuerk, A., Cook, D., Cook, J., &, Dhurjati, P., Maximum recommended dosage of lithium for pregnant women based on a PBPK model for lithium absorption. Adv. Bioinformatics 2012, 352729 (2012).
11. Chou, L.Y., &, Chan, W.C., Fluorescence-tagged gold nanoparticles for rapidly characterizing the size-dependent biodistribution in tumor models. Adv. Healthc. Mater. 1, 714-721 (2012).
12. Hainfeld, J.F., Slatkin, D.N., Focella, T.M., &, Smilowitz, H.M., Gold nanoparticles: a new X-ray contrast agent. Br. J. Radiol. 79, 248-253 (2006).
13. Cheng, Y., Meyers, J.D., Broome, A.M., Kenney, M.E., Basilion, J.P., &, Burda C,. Deep penetration of a PDT drug into tumors by noncovalent drug-gold nanoparticle conjugates. J. Am. Chem. Soc. 133, 2583-2591 (2011).
14. Loginova, Y.F., et al,. Biodistribution of intact fluorescent CdSe/CdS/ZnS quantum dots coated by mercaptopropionic acid after intravenous injection into mice. J. Biophotonics 5, 848-859 (2012).
15. Paciotti G.F., et al,. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 11, 169-183 (2004).
16. Lin, P., et al,. Computational and ultrastructural toxicology of a nanoparticle, Quantum Dot 705, in mice. Environ. Sci. Technol. 42, 6264-6270 (2008).
17. Krishnan, V., et al,. Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine. Mol. Pharm. 10, 2199-2210 (2013).
18. Gaynon, P.S., &, Carrel, A.L., Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv. Exp. Med. Biol. 457, 593-605 (1999).
19. Stuart, F.A., Segal, T.Y., &, Keady, S., Adverse psychological effects of corticosteroids in children and adolescents. Arch. Dis. Child. 90, 500-506 (2005).
20. Krishnan, V., &, Rajasekaran, A.K., Clinical nanomedicine: a solution to the chemotherapy conundrum in pediatric leukemia therapy. Clin. Pharmacol. Ther. 95, 168-178 (2014).
21. Tan, J., Thomas, A., &, Liu, Y., Influence of red blood cells on nanoparticle targeted delivery in microcirculation. Soft Matter 8, 1934-1946 (2011).
22. Bazemore, A.W., &, Smucker, D.R., Lymphadenopathy and malignancy. Am. Fam. Physician 66, 2103-2110 (2002).
23. Murray, R.A., Thom, G., Gardner, R.V., &, Craver, R.D., Infant acute lymphoblastic leukemia: a 20-year children's hospital experience. Fetal Pediatr. Pathol. 27, 197-205 (2008).